{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:56:00Z","timestamp":1793908560654,"version":"4.8.0"},"reference-count":158,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41582-025-01089-4","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:39:35Z","timestamp":1746185975000},"page":"312-326","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Autoimmune encephalitis-associated epilepsy"],"prefix":"10.1038","volume":"21","author":[{"given":"Claude","family":"Steriade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5802-8047","authenticated-orcid":false,"given":"Jan","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian G.","family":"Bien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"1089_CR1","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/j.0013-9580.2005.66104.x","volume":"46","author":"RS Fisher","year":"2005","unstructured":"Fisher, R. S. et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 46, 470\u2013472 (2005).","journal-title":"Epilepsia"},{"key":"1089_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1600-0404.1985.tb00855.x","volume":"72","author":"O Eeg-Olofsson","year":"1985","unstructured":"Eeg-Olofsson, O., Prchal, J. F. & Andermann, F. Abnormalities of T-lymphocyte subsets in epileptic patients. Acta Neurol. Scand. 72, 140\u2013144 (1985).","journal-title":"Acta Neurol. Scand."},{"key":"1089_CR3","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1528-1157.1980.tb04295.x","volume":"21","author":"JA Aarli","year":"1980","unstructured":"Aarli, J. A. & Fontana, A. Immunological aspects of epilepsy. Epilepsia 21, 451\u2013457 (1980).","journal-title":"Epilepsia"},{"key":"1089_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/0006-8993(73)90268-0","volume":"59","author":"SE Karpiak Jr.","year":"1973","unstructured":"Karpiak, S. E. Jr., Bowen, F. P. & Rapport, M. M. Epileptiform activity induced by antiserum to synaptic membrane. Brain Res. 59, 303\u2013310 (1973).","journal-title":"Brain Res."},{"key":"1089_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0006-8993(71)90157-0","volume":"32","author":"LT Mihailovi\u0107","year":"1971","unstructured":"Mihailovi\u0107, L. T. & Cupi\u0107, D. Epileptiform activity evoked by intracerebral injection of anti-brain antibodies. Brain Res. 32, 97\u2013124 (1971).","journal-title":"Brain Res."},{"key":"1089_CR6","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/epi.16807","volume":"62","author":"AK Yeshokumar","year":"2021","unstructured":"Yeshokumar, A. K. et al. Seizures in autoimmune encephalitis \u2013 a systematic review and quantitative synthesis. Epilepsia 62, 397\u2013407 (2021).","journal-title":"Epilepsia"},{"key":"1089_CR7","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/jamaneurol.2021.3113","volume":"78","author":"C Steriade","year":"2021","unstructured":"Steriade, C. et al. Discerning the role of autoimmunity and autoantibodies in epilepsy: a review. JAMA Neurol. 78, 1383\u20131390 (2021).","journal-title":"JAMA Neurol."},{"key":"1089_CR8","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/j.1528-1167.2009.02285.x","volume":"51","author":"E Beghi","year":"2010","unstructured":"Beghi, E. et al. Recommendation for a definition of acute symptomatic seizure. Epilepsia 51, 671\u2013675 (2010).","journal-title":"Epilepsia"},{"key":"1089_CR9","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1056\/NEJMra1708712","volume":"378","author":"J Dalmau","year":"2018","unstructured":"Dalmau, J. & Graus, F. Antibody-mediated encephalitis. N. Engl. J. Med. 378, 840\u2013851 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1089_CR10","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/epi.16571","volume":"61","author":"C Steriade","year":"2020","unstructured":"Steriade, C. et al. Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: conceptual definitions. Epilepsia 61, 1341\u20131351 (2020).","journal-title":"Epilepsia"},{"key":"1089_CR11","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1111\/epi.17699","volume":"64","author":"A Rada","year":"2023","unstructured":"Rada, A. & Bien, C. G. What is autoimmune encephalitis-associated epilepsy? Proposal of a practical definition. Epilepsia 64, 2249\u20132255 (2023).","journal-title":"Epilepsia"},{"key":"1089_CR12","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/epi.17478","volume":"64","author":"A Budhram","year":"2022","unstructured":"Budhram, A. & Burneo, J. G. Acute symptomatic seizures, epilepsy, and autoimmune encephalitis: clarifying terminology in neural antibody\u2010associated disease. Epilepsia 64, 306\u2013310 (2022).","journal-title":"Epilepsia"},{"key":"1089_CR13","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1172\/JCI125178","volume":"129","author":"C Geis","year":"2019","unstructured":"Geis, C., Planagum\u00e0, J., Carre\u00f1o, M., Graus, F. & Dalmau, J. Autoimmune seizures and epilepsy. J. Clin. Invest. 129, 926\u2013940 (2019).","journal-title":"J. Clin. Invest."},{"key":"1089_CR14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/epi.12550","volume":"55","author":"RS Fisher","year":"2014","unstructured":"Fisher, R. S. et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 55, 475\u2013482 (2014).","journal-title":"Epilepsia"},{"key":"1089_CR15","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJM199802123380704","volume":"338","author":"WA Hauser","year":"1998","unstructured":"Hauser, W. A., Rich, S. S., Lee, J. R., Annegers, J. F. & Anderson, V. E. Risk of recurrent seizures after two unprovoked seizures. N. Engl. J. Med. 338, 429\u2013434 (1998).","journal-title":"N. Engl. J. Med."},{"key":"1089_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/1531-8249(200001)47:1<9::AID-ANA5>3.0.CO;2-I","volume":"47","author":"ML Albert","year":"2000","unstructured":"Albert, M. L., Austin, L. M. & Darnell, R. B. Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann. Neurol. 47, 9\u201317 (2000).","journal-title":"Ann. Neurol."},{"key":"1089_CR17","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/3315","volume":"4","author":"ML Albert","year":"1998","unstructured":"Albert, M. L. et al. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat. Med. 4, 1321\u20131324 (1998).","journal-title":"Nat. Med."},{"key":"1089_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S1474-4422(13)70260-6","volume":"13","author":"S Varadkar","year":"2014","unstructured":"Varadkar, S. et al. Rasmussen\u2019s encephalitis: clinical features, pathobiology, and treatment advances. Lancet Neurol. 13, 195\u2013205 (2014).","journal-title":"Lancet Neurol."},{"key":"1089_CR19","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1136\/jnnp-2020-325275","volume":"92","author":"A Budhram","year":"2021","unstructured":"Budhram, A. et al. Clinical spectrum of high-titre GAD65 antibodies. J. Neurol. Neurosurg. Psychiatry 92, 645\u2013654 (2021).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1089_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120540","volume":"445","author":"M Madlener","year":"2023","unstructured":"Madlener, M. et al. Glutamic acid decarboxylase antibody-associated neurological syndromes: clinical and antibody characteristics and therapy response. J. Neurol. Sci. 445, 120540 (2023).","journal-title":"J. Neurol. Sci."},{"key":"1089_CR21","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000696","volume":"7","author":"A Mu\u00f1oz-Lopetegi","year":"2020","unstructured":"Mu\u00f1oz-Lopetegi, A. et al. Neurologic syndromes related to anti-GAD65: clinical and serologic response to treatment. Neurol. Neuroimmunol. Neuroinflamm. 7, e696 (2020).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1089_CR22","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1007\/s00415-020-09814-3","volume":"267","author":"CG Bien","year":"2020","unstructured":"Bien, C. G. et al. Routine diagnostics for neural antibodies, clinical correlates, treatment and functional outcome. J. Neurol. 267, 2101\u20132114 (2020).","journal-title":"J. Neurol."},{"key":"1089_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.990553","volume":"13","author":"L Bai","year":"2022","unstructured":"Bai, L. et al. Neurological disorders associated with glutamic acid decarboxylase 65 antibodies: clinical spectrum and prognosis of a cohort from China. Front. Neurol. 13, 990553 (2022).","journal-title":"Front. Neurol."},{"key":"1089_CR24","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/brain\/awac404","volume":"146","author":"AR Tr\u00f6scher","year":"2023","unstructured":"Tr\u00f6scher, A. R. et al. Temporal lobe epilepsy with GAD antibodies: neurons killed by T cells not by complement membrane attack complex. Brain 146, 1436\u20131452 (2023).","journal-title":"Brain"},{"key":"1089_CR25","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.seizure.2021.02.010","volume":"86","author":"M Ilyas-Feldmann","year":"2021","unstructured":"Ilyas-Feldmann, M., Pr\u00fc\u00df, H. & Holtkamp, M. Long-term seizure outcome and antiseizure medication use in autoimmune encephalitis. Seizure 86, 138\u2013143 (2021).","journal-title":"Seizure"},{"key":"1089_CR26","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/ana.26013","volume":"89","author":"M de Bruijn","year":"2021","unstructured":"de Bruijn, M. et al. Antibodies contributing to focal epilepsy signs and symptoms score. Ann. Neurol. 89, 698\u2013710 (2021).","journal-title":"Ann. Neurol."},{"key":"1089_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-015-0435-9","volume":"15","author":"S Fauser","year":"2015","unstructured":"Fauser, S. et al. Long latency between GAD-antibody detection and development of limbic encephalitis \u2013 a case report. BMC Neurol. 15, 177 (2015).","journal-title":"BMC Neurol."},{"key":"1089_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1159\/000519229","volume":"29","author":"X Fan","year":"2022","unstructured":"Fan, X. et al. Clinical heterogeneity in acute symptomatic seizures due to autoimmune encephalitis related to GAD65 antibodies. Neuroimmunomodulation 29, 171\u2013176 (2022).","journal-title":"Neuroimmunomodulation"},{"key":"1089_CR29","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200034","volume":"9","author":"T Kaaden","year":"2022","unstructured":"Kaaden, T. et al. Seizure semiology in antibody-associated autoimmune encephalitis. Neurol. Neuroimmunol. Neuroinflamm. 9, e200034 (2022).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1089_CR30","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1007\/s00415-020-09807-2","volume":"267","author":"B Joubert","year":"2020","unstructured":"Joubert, B. et al. Long-term outcomes in temporal lobe epilepsy with glutamate decarboxylase antibodies. J. Neurol. 267, 2083\u20132089 (2020).","journal-title":"J. Neurol."},{"key":"1089_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03182-x","volume":"23","author":"N Lin","year":"2023","unstructured":"Lin, N. et al. Seizure semiology and predictors of outcomes in Chinese patients with glutamic acid decarboxylase antibody-associated neurological syndrome. BMC Neurol. 23, 149 (2023).","journal-title":"BMC Neurol."},{"key":"1089_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577289","volume":"345","author":"L Chengyu","year":"2020","unstructured":"Chengyu, L. et al. Clinical features and immunotherapy outcomes of anti-glutamic acid decarboxylase 65 antibody-associated neurological disorders. J. Neuroimmunol. 345, 577289 (2020).","journal-title":"J. Neuroimmunol."},{"key":"1089_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.seizure.2022.03.025","volume":"98","author":"F Pondrelli","year":"2022","unstructured":"Pondrelli, F. et al. Pilomotor seizures in autoimmune limbic encephalitis: description of two GAD65 antibodies \u2013 related cases and literature review. Seizure 98, 71\u201378 (2022).","journal-title":"Seizure"},{"key":"1089_CR34","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1111\/epi.16888","volume":"62","author":"KM Smith","year":"2021","unstructured":"Smith, K. M. et al. Musicogenic epilepsy: expanding the spectrum of glutamic acid decarboxylase 65 neurological autoimmunity. Epilepsia 62, e76\u2013e81 (2021).","journal-title":"Epilepsia"},{"key":"1089_CR35","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/ane.12799","volume":"137","author":"M Falip","year":"2018","unstructured":"Falip, M. et al. Musicogenic reflex seizures in epilepsy with glutamic acid decarbocylase antibodies. Acta Neurol. Scand. 137, 272\u2013276 (2018).","journal-title":"Acta Neurol. Scand."},{"key":"1089_CR36","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3389\/fneur.2018.01143","volume":"9","author":"M Falip","year":"2018","unstructured":"Falip, M. et al. Hippocampus and insula are targets in epileptic patients with glutamic acid decarboxylase antibodies. Front. Neurol. 9, 1143 (2018).","journal-title":"Front. Neurol."},{"key":"1089_CR37","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/epi.17185","volume":"63","author":"C Barba","year":"2022","unstructured":"Barba, C. et al. Surgical outcome of temporal plus epilepsy is improved by multilobar resection. Epilepsia 63, 769\u2013776 (2022).","journal-title":"Epilepsia"},{"key":"1089_CR38","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1136\/jnnp-2014-307875","volume":"86","author":"J Wagner","year":"2015","unstructured":"Wagner, J. et al. Automated volumetry of the mesiotemporal structures in antibody-associated limbic encephalitis. J. Neurol. Neurosurg. Psychiatry 86, 735\u2013742 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1089_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89010-z","volume":"11","author":"E Conde-Blanco","year":"2021","unstructured":"Conde-Blanco, E. et al. Volumetric and shape analysis of the hippocampus in temporal lobe epilepsy with GAD65 antibodies compared with non-immune epilepsy. Sci. Rep. 11, 10199 (2021).","journal-title":"Sci. Rep."},{"key":"1089_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2021.102826","volume":"32","author":"M Dade","year":"2021","unstructured":"Dade, M. et al. Quantitative brain imaging analysis of neurological syndromes associated with anti-GAD antibodies. Neuroimage Clin. 32, 102826 (2021).","journal-title":"Neuroimage Clin."},{"key":"1089_CR41","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1111\/ene.12186","volume":"20","author":"C Frisch","year":"2013","unstructured":"Frisch, C., Malter, M. P., Elger, C. E. & Helmstaedter, C. Neuropsychological course of voltage-gated potassium channel and glutamic acid decarboxylase antibody related limbic encephalitis. Eur. J. Neurol. 20, 1297\u20131304 (2013).","journal-title":"Eur. J. Neurol."},{"key":"1089_CR42","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000416","volume":"5","author":"A Belbezier","year":"2018","unstructured":"Belbezier, A. et al. Multiplex family with GAD65-Abs neurologic syndromes. Neurol. Neuroimmunol. Neuroinflamm. 5, e416 (2018).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1089_CR43","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1093\/brain\/awac119","volume":"146","author":"C Strippel","year":"2023","unstructured":"Strippel, C. et al. A genome-wide association study in autoimmune neurological syndromes with anti-GAD65 autoantibodies. Brain 146, 977\u2013990 (2023).","journal-title":"Brain"},{"key":"1089_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116860","volume":"413","author":"FS Thaler","year":"2020","unstructured":"Thaler, F. S. et al. Possible link of genetic variants to autoimmunity in GAD-antibody-associated neurological disorders. J. Neurol. Sci. 413, 116860 (2020).","journal-title":"J. Neurol. Sci."},{"key":"1089_CR45","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/epi.16914","volume":"62","author":"AR Tr\u00f6scher","year":"2021","unstructured":"Tr\u00f6scher, A. R. et al. T cell numbers correlate with neuronal loss rather than with seizure activity in medial temporal lobe epilepsy. Epilepsia 62, 1343\u20131353 (2021).","journal-title":"Epilepsia"},{"key":"1089_CR46","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/epi.13784","volume":"58","author":"J Bauer","year":"2017","unstructured":"Bauer, J. et al. Innate and adaptive immunity in human epilepsies. Epilepsia 58, 57\u201368 (2017).","journal-title":"Epilepsia"},{"key":"1089_CR47","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.1007\/s00415-024-12302-7","volume":"271","author":"W Roll","year":"2024","unstructured":"Roll, W. et al. [18F]DPA-714-PET-MRI reveals pronounced innate immunity in human anti-LGI1 and anti-CASPR2 limbic encephalitis. J. Neurol. 271, 3653\u20133659 (2024).","journal-title":"J. Neurol."},{"key":"1089_CR48","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abq7595","volume":"9","author":"M Gallus","year":"2023","unstructured":"Gallus, M. et al. Translational imaging of TSPO reveals pronounced innate inflammation in human and murine CD8 T cell-mediated limbic encephalitis. Sci. Adv. 9, eabq7595 (2023).","journal-title":"Sci. Adv."},{"key":"1089_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2022.102282","volume":"214","author":"SE Parker","year":"2022","unstructured":"Parker, S. E., Bellingham, M. C. & Woodruff, T. M. Complement drives circuit modulation in the adult brain. Prog. Neurobiol. 214, 102282 (2022).","journal-title":"Prog. Neurobiol."},{"key":"1089_CR50","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00401-022-02448-x","volume":"144","author":"O Chuquisana","year":"2022","unstructured":"Chuquisana, O. et al. Complement activation contributes to GAD antibody-associated encephalitis. Acta Neuropathol. 144, 381\u2013383 (2022).","journal-title":"Acta Neuropathol."},{"key":"1089_CR51","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/ana.25414","volume":"85","author":"FS Thaler","year":"2019","unstructured":"Thaler, F. S. et al. Abundant glutamic acid decarboxylase (GAD)-reactive B cells in GAD-antibody-associated neurological disorders. Ann. Neurol. 85, 448\u2013454 (2019).","journal-title":"Ann. Neurol."},{"key":"1089_CR52","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1097\/WCO.0b013e328359da15","volume":"25","author":"F Graus","year":"2012","unstructured":"Graus, F. & Dalmau, J. Paraneoplastic neurological syndromes. Curr. Opin. Neurol. 25, 795\u2013801 (2012).","journal-title":"Curr. Opin. Neurol."},{"key":"1089_CR53","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1093\/brain\/aws082","volume":"135","author":"CG Bien","year":"2012","unstructured":"Bien, C. G. et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 135, 1622\u20131638 (2012).","journal-title":"Brain"},{"key":"1089_CR54","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00415-020-10250-6","volume":"268","author":"A Rada","year":"2021","unstructured":"Rada, A. et al. Seizures associated with antibodies against cell surface antigens are acute symptomatic and not indicative of epilepsy: insights from long-term data. J. Neurol. 268, 1059\u20131069 (2021).","journal-title":"J. Neurol."},{"key":"1089_CR55","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3389\/fneur.2018.00579","volume":"9","author":"KM M\u00e4kel\u00e4","year":"2018","unstructured":"M\u00e4kel\u00e4, K. M., Hietaharju, A., Brander, A. & Peltola, J. Clinical management of epilepsy with glutamic acid decarboxylase antibody positivity: the interplay between immunotherapy and anti-epileptic drugs. Front. Neurol. 9, 579 (2018).","journal-title":"Front. Neurol."},{"key":"1089_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.577063","volume":"337","author":"R Di Giacomo","year":"2019","unstructured":"Di Giacomo, R. et al. Predictive value of high titer of GAD65 antibodies in a case of limbic encephalitis. J. Neuroimmunol. 337, 577063 (2019).","journal-title":"J. Neuroimmunol."},{"key":"1089_CR57","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.yebeh.2016.10.016","volume":"65","author":"N Hansen","year":"2016","unstructured":"Hansen, N. et al. Seizure control and cognitive improvement via immunotherapy in late onset epilepsy patients with paraneoplastic versus GAD65 autoantibody-associated limbic encephalitis. Epilepsy Behav. 65, 18\u201324 (2016).","journal-title":"Epilepsy Behav."},{"key":"1089_CR58","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1212\/WNL.0000000000000383","volume":"82","author":"M Toledano","year":"2014","unstructured":"Toledano, M. et al. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology 82, 1578\u20131586 (2014).","journal-title":"Neurology"},{"key":"1089_CR59","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1056\/NEJMoa1703784","volume":"377","author":"I Blumcke","year":"2017","unstructured":"Blumcke, I. et al. Histopathological findings in brain tissue obtained during epilepsy surgery. N. Engl. J. Med. 377, 1648\u20131656 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1089_CR60","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200151","volume":"10","author":"PJ Serrano-Castro","year":"2023","unstructured":"Serrano-Castro, P. J. et al. Cenobamate and clobazam combination as personalized medicine in autoimmune-associated epilepsy with anti-Gad65 antibodies. Neurol. Neuroimmunol. Neuroinflamm. 10, e200151 (2023).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1089_CR61","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001033","volume":"8","author":"JR Abbatemarco","year":"2021","unstructured":"Abbatemarco, J. R. et al. Autoimmune neurology: the need for comprehensive care. Neurol. Neuroimmunol. Neuroinflamm. 8, e1033 (2021).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1089_CR62","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.eplepsyres.2016.12.010","volume":"129","author":"M Carre\u00f1o","year":"2017","unstructured":"Carre\u00f1o, M. et al. Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies. Epilepsy Res. 129, 101\u2013105 (2017).","journal-title":"Epilepsy Res."},{"key":"1089_CR63","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.yebeh.2017.10.033","volume":"79","author":"N Hansen","year":"2018","unstructured":"Hansen, N. et al. Pre- and long-term postoperative courses of hippocampus-associated memory impairment in epilepsy patients with antibody-associated limbic encephalitis and selective amygdalohippocampectomy. Epilepsy Behav. 79, 93\u201399 (2018).","journal-title":"Epilepsy Behav."},{"key":"1089_CR64","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.1111\/epi.18086","volume":"65","author":"HH Zhao-Fleming","year":"2024","unstructured":"Zhao-Fleming, H. H., Guo, Y., Britton, J. W., Dubey, D. & Smith, K. M. Outcomes of surgical resection and vagus nerve stimulation in patients with medically refractory epilepsy and glutamic acid decarboxylase 65 antibody positivity. Epilepsia 65, e182\u2013e189 (2024).","journal-title":"Epilepsia"},{"key":"1089_CR65","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1684\/epd.2018.0993","volume":"20","author":"L Gillinder","year":"2018","unstructured":"Gillinder, L. et al. Refractory epilepsy secondary to anti-GAD encephalitis treated with DBS post SEEG evaluation: a novel case report based on stimulation findings. Epileptic Disord. 20, 451\u2013456 (2018).","journal-title":"Epileptic Disord."},{"key":"1089_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2022.106974","volume":"184","author":"B Chen","year":"2022","unstructured":"Chen, B. et al. Brain responsive neurostimulation device safety and effectiveness in patients with drug-resistant autoimmune-associated epilepsy. Epilepsy Res. 184, 106974 (2022).","journal-title":"Epilepsy Res."},{"key":"1089_CR67","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/epi4.12395","volume":"5","author":"AM Feyissa","year":"2020","unstructured":"Feyissa, A. M. et al. Brain-responsive neurostimulation treatment in patients with GAD65 antibody-associated autoimmune mesial temporal lobe epilepsy. Epilepsia Open 5, 307\u2013313 (2020).","journal-title":"Epilepsia Open"},{"key":"1089_CR68","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1111\/epi.17695","volume":"64","author":"KM Smith","year":"2023","unstructured":"Smith, K. M. et al. Seizure characteristics and outcomes in patients with neurological conditions related to high-risk paraneoplastic antibodies. Epilepsia 64, 2385\u20132398 (2023).","journal-title":"Epilepsia"},{"key":"1089_CR69","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1111\/epi.17338","volume":"63","author":"T Baumgartner","year":"2022","unstructured":"Baumgartner, T. et al. Seizure underreporting in LGI1 and CASPR2 antibody encephalitis. Epilepsia 63, e100\u2013e105 (2022).","journal-title":"Epilepsia"},{"key":"1089_CR70","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/WCO.0000000000001263","volume":"37","author":"S Mu\u00f1iz-Castrillo","year":"2024","unstructured":"Mu\u00f1iz-Castrillo, S. & Honnorat, J. Genetic predisposition to autoimmune encephalitis and paraneoplastic neurological syndromes. Curr. Opin. Neurol. 37, 329\u2013337 (2024).","journal-title":"Curr. Opin. Neurol."},{"key":"1089_CR71","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1093\/brain\/awh203","volume":"127","author":"J Dalmau","year":"2004","unstructured":"Dalmau, J. et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 127, 1831\u20131844 (2004).","journal-title":"Brain"},{"key":"1089_CR72","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00401-001-0498-0","volume":"103","author":"F Bernal","year":"2002","unstructured":"Bernal, F. et al. Immunohistochemical analysis of anti-Hu-associated paraneoplastic encephalomyelitis. Acta Neuropathol. 103, 509\u2013515 (2002).","journal-title":"Acta Neuropathol."},{"key":"1089_CR73","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1212\/01.wnl.0000223647.83708.20","volume":"67","author":"DT Blumenthal","year":"2006","unstructured":"Blumenthal, D. T. et al. Early pathologic findings and long-term improvement in anti-Ma2-associated encephalitis. Neurology 67, 146\u2013149 (2006).","journal-title":"Neurology"},{"key":"1089_CR74","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/brain\/122.1.27","volume":"122","author":"J Dalmau","year":"1999","unstructured":"Dalmau, J. et al. Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain 122, 27\u201339 (1999).","journal-title":"Brain"},{"key":"1089_CR75","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1212\/WNL.49.4.1156","volume":"49","author":"J Wanschitz","year":"1997","unstructured":"Wanschitz, J., Hainfellner, J. A., Kristoferitsch, W., Drlicek, M. & Budka, H. Ganglionitis in paraneoplastic subacute sensory neuronopathy: a morphologic study. Neurology 49, 1156\u20131159 (1997).","journal-title":"Neurology"},{"key":"1089_CR76","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/jnnp.70.2.222","volume":"70","author":"M Barnett","year":"2001","unstructured":"Barnett, M. et al. Paraneoplastic brain stem encephalitis in a woman with anti-Ma2 antibody. J. Neurol. Neurosurg. Psychiatry 70, 222\u2013225 (2001).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1089_CR77","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1212\/WNL.44.1.140","volume":"44","author":"WC Jean","year":"1994","unstructured":"Jean, W. C., Dalmau, J., Ho, A. & Posner, J. B. Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Hu-associated paraneoplastic encephalomyelitis. Neurology 44, 140\u2013147 (1994).","journal-title":"Neurology"},{"key":"1089_CR78","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1600-0404.2008.01138.x","volume":"120","author":"A Storstein","year":"2009","unstructured":"Storstein, A., Krossnes, B. K. & Vedeler, C. A. Morphological and immunohistochemical characterization of paraneoplastic cerebellar degeneration associated with Yo antibodies. Acta Neurol. Scand. 120, 64\u201367 (2009).","journal-title":"Acta Neurol. Scand."},{"key":"1089_CR79","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1212\/WNL.42.10.1931","volume":"42","author":"K Peterson","year":"1992","unstructured":"Peterson, K., Rosenblum, M. K., Kotanides, H. & Posner, J. B. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 42, 1931\u20131937 (1992).","journal-title":"Neurology"},{"key":"1089_CR80","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ctrv.2015.11.005","volume":"42","author":"MT Madondo","year":"2016","unstructured":"Madondo, M. T., Quinn, M. & Plebanski, M. Low dose cyclophosphamide: mechanisms of T cell modulation. Cancer Treat. Rev. 42, 3\u20139 (2016).","journal-title":"Cancer Treat. Rev."},{"key":"1089_CR81","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/jnnp-2020-325300","volume":"92","author":"H Abboud","year":"2021","unstructured":"Abboud, H. et al. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J. Neurol. Neurosurg. Psychiatry 92, 757\u2013768 (2021).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1089_CR82","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/brain\/124.6.1138","volume":"124","author":"F Graus","year":"2001","unstructured":"Graus, F. et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 124, 1138\u20131148 (2001).","journal-title":"Brain"},{"key":"1089_CR83","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/B978-0-12-823912-4.00015-3","volume":"200","author":"J Kerstens","year":"2024","unstructured":"Kerstens, J. & Titulaer, M. J. Overview of treatment strategies in paraneoplastic neurological syndromes. Handb. Clin. Neurol. 200, 97\u2013112 (2024).","journal-title":"Handb. Clin. Neurol."},{"key":"1089_CR84","doi-asserted-by":"publisher","first-page":"e2185","DOI":"10.1212\/WNL.0000000000007475","volume":"92","author":"M de Bruijn","year":"2019","unstructured":"de Bruijn, M. et al. Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis. Neurology 92, e2185\u2013e2196 (2019).","journal-title":"Neurology"},{"key":"1089_CR85","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1002\/acn3.51137","volume":"7","author":"CH Shen","year":"2020","unstructured":"Shen, C. H. et al. Seizures and risk of epilepsy in anti-NMDAR, anti-LGI1, and anti-GABABR encephalitis. Ann. Clin. Transl. Neurol. 7, 1392\u20131399 (2020).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1089_CR86","doi-asserted-by":"publisher","first-page":"e1141","DOI":"10.1212\/WNL.0000000000012465","volume":"97","author":"KM Smith","year":"2021","unstructured":"Smith, K. M., Dubey, D., Liebo, G. B., Flanagan, E. P. & Britton, J. W. Clinical course and features of seizures associated with LGI1-antibody encephalitis. Neurology 97, e1141\u2013e1149 (2021).","journal-title":"Neurology"},{"key":"1089_CR87","doi-asserted-by":"publisher","first-page":"5061","DOI":"10.1007\/s00415-022-11162-3","volume":"269","author":"D Guery","year":"2022","unstructured":"Guery, D. et al. Long-term evolution and prognostic factors of epilepsy in limbic encephalitis with LGI1 antibodies. J. Neurol. 269, 5061\u20135069 (2022).","journal-title":"J. Neurol."},{"key":"1089_CR88","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1111\/epi.17245","volume":"63","author":"X Liu","year":"2022","unstructured":"Liu, X. et al. Long-term seizure outcomes in patients with autoimmune encephalitis: a prospective observational registry study update. Epilepsia 63, 1812\u20131821 (2022).","journal-title":"Epilepsia"},{"key":"1089_CR89","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.yebeh.2015.08.037","volume":"52","author":"W L\u00f6scher","year":"2015","unstructured":"L\u00f6scher, W., Hirsch, L. J. & Schmidt, D. The enigma of the latent period in the development of symptomatic acquired epilepsy \u2013 traditional view versus new concepts. Epilepsy Behav. 52, 78\u201392 (2015).","journal-title":"Epilepsy Behav."},{"key":"1089_CR90","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.0013-9580.2004.09004.x","volume":"45","author":"HG Wieser","year":"2004","unstructured":"Wieser, H. G. ILAE Commission report. Mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsia 45, 695\u2013714 (2004).","journal-title":"Epilepsia"},{"key":"1089_CR91","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.yebeh.2018.10.038","volume":"94","author":"W Zhang","year":"2019","unstructured":"Zhang, W., Wang, X., Shao, N., Ma, R. & Meng, H. Seizure characteristics, treatment, and outcome in autoimmune synaptic encephalitis: a long-term study. Epilepsy Behav. 94, 198\u2013203 (2019).","journal-title":"Epilepsy Behav."},{"key":"1089_CR92","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jocn.2019.07.049","volume":"68","author":"L Yao","year":"2019","unstructured":"Yao, L. et al. Clinical features and long-term outcomes of seizures associated with autoimmune encephalitis: a follow-up study in East China. J. Clin. Neurosci. 68, 73\u201379 (2019).","journal-title":"J. Clin. Neurosci."},{"key":"1089_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2023.107854","volume":"231","author":"C Steriade","year":"2023","unstructured":"Steriade, C. et al. Predictors of seizure outcomes of autoimmune encephalitis: a clinical and morphometric quantitative analysis study. Clin. Neurol. Neurosurg. 231, 107854 (2023).","journal-title":"Clin. Neurol. Neurosurg."},{"key":"1089_CR94","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1093\/brain\/awy109","volume":"141","author":"S Binks","year":"2018","unstructured":"Binks, S. et al. Distinct HLA associations of LGI1 and CASPR2-antibody diseases. Brain 141, 2263\u20132271 (2018).","journal-title":"Brain"},{"key":"1089_CR95","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200103","volume":"10","author":"Y Segal","year":"2023","unstructured":"Segal, Y. et al. New insights on DR and DQ human leukocyte antigens in anti-LGI1 encephalitis. Neurol. Neuroimmunol. Neuroinflamm. 10, e200103 (2023).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1089_CR96","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001140","volume":"9","author":"V Peris Sempere","year":"2022","unstructured":"Peris Sempere, V. et al. Human leukocyte antigen association study reveals DRB1*04:02 effects additional to DRB1*07:01 in anti-LGI1 encephalitis. Neurol. Neuroimmunol. Neuroinflamm. 9, e1140 (2022).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1089_CR97","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1136\/jnnp-2020-323226","volume":"91","author":"S Mu\u00f1iz-Castrillo","year":"2020","unstructured":"Mu\u00f1iz-Castrillo, S. et al. Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features. J. Neurol. Neurosurg. Psychiatry 91, 1076\u20131084 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1089_CR98","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200221","volume":"11","author":"X Liu","year":"2024","unstructured":"Liu, X. et al. Genome-wide association study identifies IFIH1 and HLA-DQB1*05:02 loci associated with anti-NMDAR encephalitis. Neurol. Neuroimmunol. Neuroinflamm. 11, e200221 (2024).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1089_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1423149","volume":"15","author":"V Peris Sempere","year":"2024","unstructured":"Peris Sempere, V. et al. HLA and KIR genetic association and NK cells in anti-NMDAR encephalitis. Front. Immunol. 15, 1423149 (2024).","journal-title":"Front. Immunol."},{"key":"1089_CR100","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.pediatrneurol.2022.06.014","volume":"134","author":"K Anurat","year":"2022","unstructured":"Anurat, K. et al. HLA-DRB1\u22171502 is associated with anti-N-methyl-D-aspartate receptor encephalitis in Thai children. Pediatr. Neurol. 134, 93\u201399 (2022).","journal-title":"Pediatr. Neurol."},{"key":"1089_CR101","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/bpa.12818","volume":"30","author":"JC Kuehn","year":"2020","unstructured":"Kuehn, J. C. et al. A 64-year-old patient with a mesiotemporal mass and symptomatic epilepsy. Brain Pathol. 30, 413\u2013414 (2020).","journal-title":"Brain Pathol."},{"key":"1089_CR102","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000075","volume":"2","author":"P K\u00f6rtvelyessy","year":"2015","unstructured":"K\u00f6rtvelyessy, P. et al. Complement-associated neuronal loss in a patient with CASPR2 antibody-associated encephalitis. Neurol. Neuroimmunol. Neuroinflamm. 2, e75 (2015).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1089_CR103","first-page":"3144","volume":"141","author":"M Petit-Pedrol","year":"2018","unstructured":"Petit-Pedrol, M. et al. LGI1 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity and memory. Brain 141, 3144\u20133159 (2018).","journal-title":"Brain"},{"key":"1089_CR104","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/ana.25120","volume":"83","author":"KR Patterson","year":"2018","unstructured":"Patterson, K. R., Dalmau, J. & Lancaster, E. Mechanisms of Caspr2 antibodies in autoimmune encephalitis and neuromyotonia. Ann. Neurol. 83, 40\u201351 (2018).","journal-title":"Ann. Neurol."},{"key":"1089_CR105","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00415-019-09686-2","volume":"267","author":"M Boyko","year":"2020","unstructured":"Boyko, M., Au, K. L. K., Casault, C., de Robles, P. & Pfeffer, G. Systematic review of the clinical spectrum of CASPR2 antibody syndrome. J. Neurol. 267, 1137\u20131146 (2020).","journal-title":"J. Neurol."},{"key":"1089_CR106","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jamaneurol.2016.4226","volume":"74","author":"C Finke","year":"2017","unstructured":"Finke, C. et al. Evaluation of cognitive deficits and structural hippocampal damage in encephalitis with leucine-rich, glioma-inactivated 1 antibodies. JAMA Neurol. 74, 50\u201359 (2017).","journal-title":"JAMA Neurol."},{"key":"1089_CR107","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1093\/brain\/awx070","volume":"140","author":"TD Miller","year":"2017","unstructured":"Miller, T. D. et al. Focal CA3 hippocampal subfield atrophy following LGI1 VGKC-complex antibody limbic encephalitis. Brain 140, 1212\u20131219 (2017).","journal-title":"Brain"},{"key":"1089_CR108","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1212\/WNL.0000000000003009","volume":"87","author":"H Ari\u00f1o","year":"2016","unstructured":"Ari\u00f1o, H. et al. Anti-LGI1-associated cognitive impairment: presentation and long-term outcome. Neurology 87, 759\u2013765 (2016).","journal-title":"Neurology"},{"key":"1089_CR109","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/acn3.561","volume":"5","author":"A Gadoth","year":"2018","unstructured":"Gadoth, A. et al. Elevated LGI1-IgG CSF index predicts worse neurological outcome. Ann. Clin. Transl. Neurol. 5, 646\u2013650 (2018).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1089_CR110","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000974","volume":"8","author":"S Mu\u00f1iz-Castrillo","year":"2021","unstructured":"Mu\u00f1iz-Castrillo, S. et al. Clinical and prognostic value of immunogenetic characteristics in anti-LGI1 encephalitis. Neurol. Neuroimmunol. Neuroinflamm. 8, e974 (2021).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1089_CR111","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1001\/jamaneurol.2016.1585","volume":"73","author":"B Joubert","year":"2016","unstructured":"Joubert, B. et al. Characterization of a subtype of autoimmune encephalitis with anti-contactin-associated protein-like 2 antibodies in the cerebrospinal fluid, prominent limbic symptoms, and seizures. JAMA Neurol. 73, 1115\u20131124 (2016).","journal-title":"JAMA Neurol."},{"key":"1089_CR112","doi-asserted-by":"publisher","first-page":"6325","DOI":"10.1007\/s00415-024-12594-9","volume":"271","author":"CG Bien","year":"2024","unstructured":"Bien, C. G. et al. LGI1 encephalitis: potentially complement-activating anti-LGI1-IgG subclasses 1\/2\/3 are associated with the development of hippocampal sclerosis. J. Neurol. 271, 6325\u20136335 (2024).","journal-title":"J. Neurol."},{"key":"1089_CR113","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/brain\/awx323","volume":"141","author":"J Thompson","year":"2018","unstructured":"Thompson, J. et al. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain 141, 348\u2013356 (2018).","journal-title":"Brain"},{"key":"1089_CR114","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1097\/WNR.0000000000000851","volume":"28","author":"A Filatenkov","year":"2017","unstructured":"Filatenkov, A. et al. Persistence of parenchymal and perivascular T-cells in treatment-refractory anti-N-methyl-D-aspartate receptor encephalitis. Neuroreport 28, 890\u2013895 (2017).","journal-title":"Neuroreport"},{"key":"1089_CR115","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/ana.21050","volume":"61","author":"J Dalmau","year":"2007","unstructured":"Dalmau, J. et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann. Neurol. 61, 25\u201336 (2007).","journal-title":"Ann. Neurol."},{"key":"1089_CR116","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1002\/ana.26223","volume":"90","author":"T Zrzavy","year":"2021","unstructured":"Zrzavy, T. et al. Neuropathological variability within a spectrum of NMDAR-encephalitis. Ann. Neurol. 90, 725\u2013737 (2021).","journal-title":"Ann. Neurol."},{"key":"1089_CR117","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1111\/j.1468-1331.2010.03180.x","volume":"18","author":"JP Camdessanch\u00e9","year":"2011","unstructured":"Camdessanch\u00e9, J. P. et al. Brain immunohistopathological study in a patient with anti-NMDAR encephalitis. Eur. J. Neurol. 18, 929\u2013931 (2011).","journal-title":"Eur. J. Neurol."},{"key":"1089_CR118","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1212\/WNL.0b013e318228c136","volume":"77","author":"E Martinez-Hernandez","year":"2011","unstructured":"Martinez-Hernandez, E. et al. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology 77, 589\u2013593 (2011).","journal-title":"Neurology"},{"key":"1089_CR119","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00401-009-0582-4","volume":"118","author":"E T\u00fcz\u00fcn","year":"2009","unstructured":"T\u00fcz\u00fcn, E. et al. Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. Acta Neuropathol. 118, 737\u2013743 (2009).","journal-title":"Acta Neuropathol."},{"key":"1089_CR120","doi-asserted-by":"publisher","first-page":"5866","DOI":"10.1523\/JNEUROSCI.0167-10.2010","volume":"30","author":"EG Hughes","year":"2010","unstructured":"Hughes, E. G. et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J. Neurosci. 30, 5866\u20135875 (2010).","journal-title":"J. Neurosci."},{"key":"1089_CR121","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1093\/jnen\/nlz052","volume":"78","author":"M Hirano","year":"2019","unstructured":"Hirano, M. et al. Pathological findings in male patients with anti-N-methyl-d-aspartate receptor encephalitis. J. Neuropathol. Exp. Neurol. 78, 735\u2013741 (2019).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"1089_CR122","first-page":"1305","volume":"70","author":"Y Dauvilliers","year":"2013","unstructured":"Dauvilliers, Y. et al. Hypothalamic immunopathology in anti-Ma-associated diencephalitis with narcolepsy-cataplexy. JAMA Neurol. 70, 1305\u20131310 (2013).","journal-title":"JAMA Neurol."},{"key":"1089_CR123","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.biopsych.2015.02.024","volume":"79","author":"C Finke","year":"2016","unstructured":"Finke, C. et al. Structural hippocampal damage following anti-N-methyl-D-aspartate receptor encephalitis. Biol. Psychiatry 79, 727\u2013734 (2016).","journal-title":"Biol. Psychiatry"},{"key":"1089_CR124","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00415-021-10643-1","volume":"269","author":"J Xu","year":"2022","unstructured":"Xu, J. et al. Progressive cortical and sub-cortical alterations in patients with anti-N-methyl-d-aspartate receptor encephalitis. J. Neurol. 269, 389\u2013398 (2022).","journal-title":"J. Neurol."},{"key":"1089_CR125","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/brain\/awu310","volume":"138","author":"J Planagum\u00e0","year":"2015","unstructured":"Planagum\u00e0, J. et al. Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain 138, 94\u2013109 (2015).","journal-title":"Brain"},{"key":"1089_CR126","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/ana.24293","volume":"77","author":"X Peng","year":"2015","unstructured":"Peng, X. et al. Cellular plasticity induced by anti-\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies. Ann. Neurol. 77, 381\u2013398 (2015).","journal-title":"Ann. Neurol."},{"key":"1089_CR127","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S1474-4422(13)70299-0","volume":"13","author":"M Petit-Pedrol","year":"2014","unstructured":"Petit-Pedrol, M. et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol. 13, 276\u2013286 (2014).","journal-title":"Lancet Neurol."},{"key":"1089_CR128","doi-asserted-by":"publisher","first-page":"8151","DOI":"10.1523\/JNEUROSCI.4415-13.2014","volume":"34","author":"T Ohkawa","year":"2014","unstructured":"Ohkawa, T. et al. Identification and characterization of GABAA receptor autoantibodies in autoimmune encephalitis. J. Neurosci. 34, 8151\u20138163 (2014).","journal-title":"J. Neurosci."},{"key":"1089_CR129","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/acn3.50974","volume":"7","author":"A Bracher","year":"2020","unstructured":"Bracher, A. et al. An expanded parenchymal CD8+ T cell clone in GABAA receptor encephalitis. Ann. Clin. Transl. Neurol. 7, 239\u2013244 (2020).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1089_CR130","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000232","volume":"3","author":"KS Golombeck","year":"2016","unstructured":"Golombeck, K. S. et al. Evidence of a pathogenic role for CD8+ T cells in anti-GABAB receptor limbic encephalitis. Neurol. Neuroimmunol. Neuroinflamm. 3, e232 (2016).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1089_CR131","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s10072-023-07165-1","volume":"45","author":"D Cui","year":"2024","unstructured":"Cui, D., Feng, J., Yang, M., Dong, Y. & Lian, Y. Acute symptomatic seizures and risk of seizure recurrence in patients with anti-NMDAR, anti-LGI1, and anti-GABABR encephalitis. Neurol. Sci. 45, 1609\u20131617 (2024).","journal-title":"Neurol. Sci."},{"key":"1089_CR132","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000353","volume":"4","author":"AM Feyissa","year":"2017","unstructured":"Feyissa, A. M., L\u00f3pez Chiriboga, A. S. & Britton, J. W. Antiepileptic drug therapy in patients with autoimmune epilepsy. Neurol. Neuroimmunol. Neuroinflamm. 4, e353 (2017).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"1089_CR133","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/epi4.12226","volume":"3","author":"AM Feyissa","year":"2018","unstructured":"Feyissa, A. M. et al. Antiepileptic drug therapy in autoimmune epilepsy associated with antibodies targeting the leucine-rich glioma-inactivated protein 1. Epilepsia Open 3, 348\u2013356 (2018).","journal-title":"Epilepsia Open"},{"key":"1089_CR134","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/jnnp-2020-325302","volume":"92","author":"H Abboud","year":"2021","unstructured":"Abboud, H. et al. Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management. J. Neurol. Neurosurg. Psychiatry 92, 897\u2013907 (2021).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1089_CR135","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1111\/epi.17238","volume":"63","author":"YC Chang","year":"2022","unstructured":"Chang, Y. C., Nouri, M. N., Mirsattari, S., Burneo, J. G. & Budhram, A. \u201cObvious\u201d indications for neural antibody testing in epilepsy or seizures: the ONES checklist. Epilepsia 63, 1658\u20131670 (2022).","journal-title":"Epilepsia"},{"key":"1089_CR136","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1097\/CM9.0000000000001701","volume":"134","author":"Y Jia","year":"2021","unstructured":"Jia, Y., Wang, H. F., Zhang, M. Y. & Wang, Y. P. Antibody prevalence and immunotherapy response in Chinese patients with epilepsy and encephalopathy scores for patients with different neuronal surface antibodies. Chin. Med. J. 134, 2985\u20132991 (2021).","journal-title":"Chin. Med. J."},{"key":"1089_CR137","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.601761","volume":"12","author":"S Ding","year":"2021","unstructured":"Ding, S. et al. Validation of predictive models for autoimmune encephalitis-related antibodies to cell-surface proteins expressed in neurons: a retrospective study based in a hospital. Front. Neurol. 12, 601761 (2021).","journal-title":"Front. Neurol."},{"key":"1089_CR138","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jneuroim.2018.07.009","volume":"323","author":"D Dubey","year":"2018","unstructured":"Dubey, D. et al. Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction. J. Neuroimmunol. 323, 62\u201372 (2018).","journal-title":"J. Neuroimmunol."},{"key":"1089_CR139","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1136\/jnnp-2020-325011","volume":"92","author":"RN McGinty","year":"2021","unstructured":"McGinty, R. N. et al. Clinical features which predict neuronal surface autoantibodies in new-onset focal epilepsy: implications for immunotherapies. J. Neurol. Neurosurg. Psychiatry 92, 291\u2013294 (2021).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1089_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2024.123288","volume":"467","author":"A Morano","year":"2024","unstructured":"Morano, A. et al. Distinguishing seizures in autoimmune limbic encephalitis from mesial temporal lobe epilepsy with hippocampal sclerosis: clues of a temporal plus network. J. Neurol. Sci. 467, 123288 (2024).","journal-title":"J. Neurol. Sci."},{"key":"1089_CR141","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.924859","volume":"13","author":"A Morano","year":"2022","unstructured":"Morano, A. et al. Late-onset seizures and epilepsy: electroclinical features suggestive of autoimmune etiology. Front. Neurol. 13, 924859 (2022).","journal-title":"Front. Neurol."},{"key":"1089_CR142","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.seizure.2014.04.013","volume":"23","author":"R Rocamora","year":"2014","unstructured":"Rocamora, R. et al. Pilomotor seizures: an autonomic semiology of limbic encephalitis? Seizure 23, 670\u2013673 (2014).","journal-title":"Seizure"},{"key":"1089_CR143","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1093\/brain\/awm108","volume":"130","author":"C Barba","year":"2007","unstructured":"Barba, C., Barbati, G., Minotti, L., Hoffmann, D. & Kahane, P. Ictal clinical and scalp-EEG findings differentiating temporal lobe epilepsies from temporal \u2018plus\u2019 epilepsies. Brain 130, 1957\u20131967 (2007).","journal-title":"Brain"},{"key":"1089_CR144","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1059-1311(02)00260-1","volume":"12","author":"DW Seo","year":"2003","unstructured":"Seo, D. W., Lee, H. S., Hong, S. B., Hong, S. C. & Lee, E. K. Pilomotor seizures in frontal lobe epilepsy: case report. Seizure 12, 241\u2013244 (2003).","journal-title":"Seizure"},{"key":"1089_CR145","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1212\/WNL.35.2.286-b","volume":"35","author":"RP Lesser","year":"1985","unstructured":"Lesser, R. P., L\u00fcders, H. & Resor, S. Other reports of pilomotor seizures. Neurology 35, 286\u2013287 (1985).","journal-title":"Neurology"},{"key":"1089_CR146","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1136\/jnnp.2003.023333","volume":"75","author":"T Loddenkemper","year":"2004","unstructured":"Loddenkemper, T. et al. Localising and lateralising value of ictal piloerection. J. Neurol. Neurosurg. Psychiatry 75, 879\u2013883 (2004).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1089_CR147","doi-asserted-by":"publisher","first-page":"e172","DOI":"10.1111\/epi.17437","volume":"63","author":"A Budhram","year":"2022","unstructured":"Budhram, A., Sharma, M. & Young, G. B. Seizures in anti-Hu-associated extra-limbic encephalitis: characterization of a unique disease manifestation. Epilepsia 63, e172\u2013e177 (2022).","journal-title":"Epilepsia"},{"key":"1089_CR148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.seizure.2018.09.009","volume":"63","author":"M Elisak","year":"2018","unstructured":"Elisak, M. et al. The prevalence of neural antibodies in temporal lobe epilepsy and the clinical characteristics of seropositive patients. Seizure 63, 1\u20136 (2018).","journal-title":"Seizure"},{"key":"1089_CR149","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1007\/s00415-021-10894-y","volume":"269","author":"B Kambadja","year":"2021","unstructured":"Kambadja, B. et al. When should we test patients with epilepsy for autoimmune antibodies? Results from a French retrospective single center study. J. Neurol. 269, 3109\u20133118 (2021).","journal-title":"J. Neurol."},{"key":"1089_CR150","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S1474-4422(13)70282-5","volume":"13","author":"N Gresa-Arribas","year":"2014","unstructured":"Gresa-Arribas, N. et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol. 13, 167\u2013177 (2014).","journal-title":"Lancet Neurol."},{"key":"1089_CR151","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/ane.13228","volume":"141","author":"A Maialetti","year":"2020","unstructured":"Maialetti, A. et al. Multimodal pathway for brain tumor-related epilepsy patients: observational study. Acta Neurol. Scand. 141, 450\u2013462 (2020).","journal-title":"Acta Neurol. Scand."},{"key":"1089_CR152","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40478-020-00904-x","volume":"8","author":"RJ Slegers","year":"2020","unstructured":"Slegers, R. J. & Blumcke, I. Low-grade developmental and epilepsy associated brain tumors: a critical update 2020. Acta Neuropathol. Commun. 8, 27 (2020).","journal-title":"Acta Neuropathol. Commun."},{"key":"1089_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101691","volume":"5","author":"V Soeung","year":"2024","unstructured":"Soeung, V., Puchalski, R. B. & Noebels, J. L. The complex molecular epileptogenesis landscape of glioblastoma. Cell Rep. Med. 5, 101691 (2024).","journal-title":"Cell Rep. Med."},{"key":"1089_CR154","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","volume":"15","author":"F Graus","year":"2016","unstructured":"Graus, F. et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 15, 391\u2013404 (2016).","journal-title":"Lancet Neurol."},{"key":"1089_CR155","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-329195","author":"S Matricardi","year":"2022","unstructured":"Matricardi, S. et al. Epileptic phenotypes in autoimmune encephalitis: from acute symptomatic seizures to autoimmune-associated epilepsy. J. Neurol. Neurosurg. Psychiatry https:\/\/doi.org\/10.1136\/jnnp-2022-329195 (2022).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"1089_CR156","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/dmcn.15101","volume":"64","author":"J Gadian","year":"2022","unstructured":"Gadian, J. et al. Neurological and cognitive outcomes after antibody-negative autoimmune encephalitis in children. Dev. Med. Child. Neurol. 64, 649\u2013653 (2022).","journal-title":"Dev. Med. Child. Neurol."},{"key":"1089_CR157","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1007\/s00415-020-09855-8","volume":"267","author":"CG Bien","year":"2020","unstructured":"Bien, C. G. et al. Correction to: Routine diagnostics for neural antibodies, clinical correlates, treatment and functional outcome. J. Neurol. 267, 2115\u20132116 (2020).","journal-title":"J. Neurol."},{"key":"1089_CR158","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1001\/jamaneurol.2015.0749","volume":"72","author":"H Ari\u00f1o","year":"2015","unstructured":"Ari\u00f1o, H. et al. Paraneoplastic neurological syndromes and glutamic acid decarboxylase antibodies. JAMA Neurol. 72, 874\u2013881 (2015).","journal-title":"JAMA Neurol."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01089-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01089-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01089-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T11:05:46Z","timestamp":1749467146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-025-01089-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":158,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1089"],"URL":"https:\/\/doi.org\/10.1038\/s41582-025-01089-4","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"14 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}